

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Bernd RIEDL et al.

Serial No.: 09/889,227

Group Art Unit: 1625

Filed: January 8, 2002

Examiner: Rita J. Desai

For: Ω -CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

- Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:
- within three months of the filing date of a national application other than a CPA under § 1.53(d);
 - within three months of the actual filing date of the national phase of a PCT application; OR
 - before the mailing of a first substantive office action (including after filing of an RCE).
- Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:
- a final rejection under 37 C.F.R. 1.113;
 - termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR
 - a notice of allowance under 37 C.F.R. § 1.311; and

is accompanied by:

- the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
- a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).

Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing date of the following actions which have not been withdrawn:

- a final action under 37 C.F.R. § 1.113;
- termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
- OR a notice of allowance under 37 C.F.R. § 1.311;

AND is filed on or before payment of the issue fee; AND is accompanied by:

the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).

Statements Under 37 C.F.R. 1.97(e)

- Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.

Cited Materials

- Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No. _____, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).
- Copies of materials listed but not attached were cited in an international search report dated _____.
- Not required by 37 CFR § 1.98.
- Copies of the materials listed are attached (except for the foregoing).

Non-English Language References

- An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
- A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:

- X = document of particular relevance when it is taken alone
- Y = document of particular relevance when it is combined with another such document
- A = document defining the general state of the art
- O = non-written disclosure
- P = intercalated document
- T = document cited to understand the theory or principle underlying the invention
- E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
- D = cited in the application
- L = cited for another reason
- & = publication of member of same patent family

- Translation of other relevant information on foreign search report

[insert necessary translation here]

Other Information

Payment of Fees Due (If Any):

- A check for \$_____ covering the fee identified above is attached.
- Please charge to Deposit Account No. 13-3402 \$_____ for the fee identified above.

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Csaba Henter, Reg. No. 50,908
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: BAYER-0015-A

Date: May 24, 2006

CH:pdr

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|------------------------|--------------------------|----|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | Application Number | 09/889,227 | |
| | Filing Date | January 8, 2002 | |
| | First Named Inventor | Bernd RIEDL et al. | |
| | Group Art Unit | 1625 | |
| | Examiner Name | Rita J. Desai | |
| Sheet | 1 | of | 10 |
| | Attorney Docket Number | BAYER-0015-A | |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|----------------------|--------------------------------------|---|--|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
| | | Number | Kind Code ² (if known) | | |
| | A1 | 2002/0173507 | A1 | Santora et al. | 11-21-2002 |
| | A2 | 2002/0065283 | A1 | McMahon et al. | 05-30-2002 |
| | A3 | 2002/0065296 | A1 | Dumas et al. | 05-30-2002 |
| | A4 | 2004/0209905 | A1 | Kubo et al. | 10-21-2004 |
| | A5 | 5063247 | | Sekiya et al. | 11-05-1991 |
| | A6 | 5151344 | | Abe et al. | 09-29-1992 |
| | A7 | 5658903 | | Adams et al. | 08-19-1997 |
| | A8 | 5710094 | | Minami et al. | 01-20-1998 |
| | A9 | 5559137 | | Adams et al. | 09-24-1996 |
| | A10 | 5808080 | | Bell et al. | 09-15-1998 |
| | A11 | 6297381 | B1 | Cirillo et al. | 10-02-2001 |
| | A12 | 6310068 | B1 | Böttcher et al. | 10-30-2001 |
| | A13 | 6329415 | B1 | Cirillo et al. | 12-11-2001 |
| | A14 | 6358945 | B1 | Breitfelder et al. | 03-19-2002 |
| | A15 | 6372773 | B1 | Regan | 04-16-2002 |
| | A16 | 6492393 | B1 | Breitfelder et al. | 12-10-2002 |
| | A17 | 6525046 | B1 | Cirillo et al. | 02-25-2003 |
| | A18 | 6583282 | B1 | Zhang et al. | 06-24-2003 |
| | A19 | 6608052 | B2 | Breitfelder et al. | 08-19-2003 |
| | A20 | 3284433 | | Becker et al. | 11-08-1966 |
| | A21 | 4546191 | | Nishiyama et al. | 10-08-1985 |
| | A22 | 6380218 | | Marfat et al. | 04-30-02 |
| | A23 | 6500863 | | Qi et al. | 12-31-2002 |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|-----------------------|-------------------------|---------------------|--------------------------------------|---|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ³ |
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | B1 | WO | 02/14311 | A2 | Amgen Inc. | 02-21-2002 | | |
| | B2 | WO | 02/32872 | A1 | Eisai Co. Ltd. | 04-25-2002 | | |
| | B3 | WO | 02/44158 | A1 | Pfizer Products Inc. | 06-06-2002 | | |
| | B4 | WO | 02/07772 | A2 | Boehringer Ingelheim | 01-31-2002 | | |
| | B5 | WO | 01/04115 | A2 | Boehringer Ingelheim | 01-18-2001 | | |
| | B6 | WO | 99/62890 | A1 | Pfizer Products Inc. | 12-09-1999 | | |

| | | |
|--------------------|--|-----------------|
| Examiner Signature | | Date Considered |
|--------------------|--|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00) +

Approved for use through 10/31/2002. OMB 0651-0031
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----------------------|--------------------|--------------------------|------------------------|--------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Complete if Known | | |
| | Application Number | 09/889,227 | | | |
| | Filing Date | January 8, 2002 | | | |
| | First Named Inventor | Bernd RIEDL et al. | | | |
| | Group Art Unit | 1625 | | | |
| | Examiner Name | Rita J. Desai | | | |
| Sheet | 2 | of | 10 | Attorney Docket Number | BAYER-0015-A |

| FOREIGN PATENT DOCUMENTS (cont'd) | | | | | | | | |
|-----------------------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | B7 | JP | 01200254 | A2 | Hirabayashi Shigeto | 08-11-1989 | | |
| | B8 | JP | 01102461 | A2 | Hirabayashi Shigeto | 04-20-1989 | | |
| | B9 | JP | 01259360 | A2 | Hirabayashi Shigeto | 10-17-1989 | | |
| | B10 | JP | 01009455 | A2 | Megumi et al. | 01-12-1989 | | |
| | B11 | JP | 06075172 | B4 | Megumi et al. | 09-07-1988 | | |
| | B12 | JP | 06120039 | A2 | Hideki | 10-02-1992 | | |
| | B13 | JP | 03144634 | A2 | Shigeto et al. | 06-20-1991 | | |
| | B14 | JP | 03198049 | A2 | Jiro et al. | 12-27-1989 | | |
| | B15 | JP | 02150840 | A2 | Toshihiko et al. | 06-11-1990 | | |
| | B16 | JP | 02105016 | A2 | Hideo et al. | 04-17-1990 | | |
| | B17 | JP | 02108048 | A2 | Minoru et al. | 04-19-1990 | | |
| | B18 | JP | 02035450 | A2 | Toshihiko et al. | 07-26-1988 | | |
| | B19 | WO | 00/50425 | A1 | Boehringer Ingelheim | 08-31-2000 | | |
| | B20 | WO | 98/34929 | A1 | Smithkline Beecham | 08-13-1998 | | |
| | B21 | WO | 98/32439 | A1 | Smithkline Beecham | 07-30-1998 | | |
| | B22 | WO | 01/09088 | A1 | Kirin Beer Kabushiki | 02-08-2001 | | |
| | B23 | WO | 2005/048948 | A2 | Ambit Biosciences | 06-02-2005 | | |
| | B24 | WO | 02/062763 | A2 | Bayer Corporation | 08-15-2002 | | |
| | B25 | WO | 02/083628 | A1 | Boehringer Ingelheim | 10-24-2002 | | |
| | B26 | WO | 02/085857 | A2 | Bayer Corporation | 10-31-2002 | | |
| | B27 | WO | 02/085859 | A1 | Bayer Corporation | 10-31-2002 | | |
| | B28 | WO | 97/09973 | A2 | Univ. of California | 03-20-1997 | | |
| | B29 | WO | 03/068229 | A1 | Bayer Corporation | 08-21-2003 | | |
| | B30 | WO | 03/068746 | A1 | Bayer Corporation | 08-21-2003 | | |
| | B31 | WO | 03/099771 | A2 | Novartis AG | 12-04-2003 | | |
| | B32 | WO | 03/082272 | A1 | Chiron Corp. | 10-09-2003 | | |
| | B33 | WO | 02/059102 | A2 | Aventis Pharma | 08-01-2002 | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | |
|--|---|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO | | | Complete if Known | |
| | | | Application Number | 09/889,227 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | Filing Date | January 8, 2002 |
| | | | First Named Inventor | Bernd RIEDL et al. |
| | | | Group Art Unit | 1625 |
| | | | Examiner Name | Rita J. Desai |
| | | | Attorney Docket Number | BAYER-0015-A |
| Sheet | 3 | of | 10 | |

| FOREIGN PATENT DOCUMENTS (cont'd.) | | | | | | | | |
|------------------------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | B34 | WO | 01/07411 | A1 | Banyu Pharmaceutical | 02-01-2001 | | |
| | B35 | UK | 1110099 | | Julia | 06-07-1966 | | |
| | B36 | WO | 2004078746 | A2 | Boyer et al. | 09-16-2004 | | |
| | B37 | WO | 2005037273 | A1 | Ramurthy et al. | 04-28-2005 | | |
| | B38 | WO | 2005037285 | A1 | Ramurthy et al. | 04-28-2005 | | |
| | B39 | WO | 2005049603 | A1 | Finsinger et al. | 06-02-2005 | | |
| | B40 | WO | 2005019192 | A1 | Hoelzemann et al. | 03-03-2005 | | |
| | B41 | WO | 2004043374 | A2 | Anderson et al. | 05-27-2004 | | |
| | B42 | WO | 2005042520 | A1 | Stahle et al. | 05-12-2005 | | |
| | B43 | WO | 2005037829 | A1 | Stahle et al. | 04-28-2005 | | |
| | B44 | WO | 2005004864 | A1 | Buchstaller et al. | 01-20-2005 | | |
| | B45 | WO | 2004037789 | A2 | Buchstaller et al. | 05-06-2004 | | |
| | B46 | WO | 2005047283 | A1 | Hoelzemann et al. | 05-26-2005 | | |
| | B47 | WO | 2005002673 | A1 | Gill et al. | 01-13-2005 | | |
| | B48 | WO | 02059081 | A2 | Hocker et al. | 08-01-2002 | | |
| | B49 | WO | 2005004863 | A1 | Buchstaller et al. | 01-20-2005 | | |
| | B50 | WO | 2005032548 | A1 | Amiri et al. | 04-14-2005 | | |
| | B51 | WO | 2004085425 | A1 | Dipietro et al. | 10-07-2004 | | |
| | B52 | WO | 0055152 | A1 | Cirillo et al. | 09-21-2000 | | |
| | B53 | WO | 0157008 | A1 | Cusack et al. | 08-09-2001 | | |
| | B54 | WO | 2005058832 | A1 | Finsinger et al. | 06-30-2005 | | |
| | B55 | WO | 2005005389 | A2 | Bruge et al. | 01-20-2005 | | |
| | B56 | WO | 2004085399 | A1 | Buchstaller et al. | 10-07-2004 | | |
| | B57 | WO | 02083642 | A1 | Breitfelder et al. | 10-24-2002 | | |
| | B58 | WO | 0071532 | A1 | Gant et al. | 11-30-2000 | | |
| | B59 | WO | 0210141 | A1 | Ahlganian et al. | 02-07-2002 | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|--------------------------|--------------------|--|
| Substitute for form 1449A/PTO | | | Complete If Known | | |
| | | | Application Number | 09/889,227 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | Filing Date | January 8, 2002 | |
| | | | First Named Inventor | Bernd RIEDL et al. | |
| | | | Group Art Unit | 1625 | |
| | | | Examiner Name | Rita J. Desai | |
| | | | Attorney Docket Number | BAYER-0015-A | |
| Sheet | 4 | of | 10 | | |

| FOREIGN PATENT DOCUMENTS (cont'd.) | | | | | | | | |
|------------------------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁵ |
| | | Office ² | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | B60 | WO | 0214281 | A1 | Cochran et al. | 02-21-2002 | | |
| | B61 | WO | 2004019941 | A1 | Buchstaller et al. | 03-11-2004 | | |
| | B62 | WO | 0035454 | A1 | Ko et al. | 06-22-2000 | | |
| | B63 | WO | 0104115 | A2 | Zhang et al. | 01-18-2001 | | |
| | B64 | WO | 0218346 | A1 | Cooper et al. | 03-07-2002 | | |
| | B65 | WO | 0026203 | A1 | Pevarello et al. | 05-11-2000 | | |
| | B66 | WO | 0043366 | A1 | Kirin et al. | 07-27-2000 | | |
| | B67 | WO | 0056331 | A1 | Stamos et al. | 09-28-2000 | | |
| | B68 | WO | 9820868 | A1 | Tracey et al. | 05-22-1998 | | |
| | B69 | WO | 9203413 | A1 | Lythgoe et al. | 03-05-1992 | | |
| | B70 | WO | 03047523 | A2 | Lyons et al. | 06-12-2003 | | |
| | B71 | WO | 03068228 | A1 | Dumas et al. | 08-21-2003 | | |
| | B72 | WO | 02092576 | A1 | Cirillo et al. | 11-21-2002 | | |
| | B73 | WO | 9845268 | A1 | Marfat et al. | 10-15-1998 | | |
| | B74 | EP | 1256587 | A1 | Omura et al. | 11-13-2002 | | |
| | B75 | EP | 1199306 | A1 | Hayama et al. | 04-24-2002 | | |
| | B76 | EP | 0709225 | B1 | Minami et al. | 08-05-1998 | | |
| | B77 | EP | 0425443 | A1 | Oechslein et al. | 05-02-1991 | | |
| | B78 | EP | 0690344 | A1 | Sugita et al. | 01-03-1996 | | |
| | B79 | WO | 9928305 | A1 | Walker | 06-10-1999 | | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C1 | Nickel et al., "Carboxylic acid analogues of suramin, potential filaricides," <i>Indian Journal of Chemistry</i> , Vol. 30B, February 1991, p. 182-187 | |
| | C2 | Duam et al., "The ins and outs of Raf kinases," <i>TIBS</i> 19, November 1994, p. 474-480. | |
| | C3 | Campbell et al., "Increasing complexity of Ras signaling," <i>Oncogene</i> , (1998) 17, 1395-1413 | |
| | C4 | Bolton et al., "Ras oncogene directed approaches in cancer chemotherapy," <i>Annual Reports in Medicinal Chemistry</i> , 29, pp. 165-174 | |
| | C5 | Moelling et al., "Signal transduction as target of gene therapy," <i>Institute of Medical Virology, University of Zürich, Recent Results in Cancer Research</i> , Vol. 142, pp. 63-71 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | |
|---|---|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO | | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 09/889,227 |
| | | | Filing Date | January 8, 2002 |
| | | | First Named Inventor | Bernd RIEDL et al. |
| | | | Group Art Unit | 1625 |
| | | | Examiner Name | Rita J. Desai |
| | | | Attorney Docket Number | BAYER-0015-A |
| Sheet | 5 | of | 10 | |

| NON PATENT LITERATURE DOCUMENTS (cont'd.) | | | |
|---|-----------------------|---|----------------|
| Examiner initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C6 | Jay H. Stein, Internal Medicine, 4 th Edition, 1994, pp. 699-715 | |
| | C7 | Johannes L. Bos, "Ras oncogenes in human cancer: a review," <i>Cancer Research</i> , 49, 4682-4689, September 1, 1989 | |
| | C8 | Kempton et al., "Synthese potentieller Pflanzenschutz- und Schädlingsbekämpfungsmittel aus substituierten Anilinen," Pädagogische Hochschule, Eingegangen am 1.7.1982, 101-120 | |
| | C9 | Lyons et al., "Discovery of a novel Raf kinase inhibitor," <i>Endocrine-Related Cancer</i> , (2001) 8, 219-225 | |
| | C10 | Lowinger et al., "Design and discovery of small molecules targeting Raf-1 kinase," <i>Current Pharmaceutical Design</i> , 2002, 8, 2269-2278 | |
| | C11 | Dumas et al., "Recent developments in the discovery of protein kinase inhibitors from the urea class," <i>Current Opinion in Drug Discovery & Development</i> , 2004, 7(5):600-616 | |
| | C12 | Dumas, "Protein kinase inhibitors from the urea class," <i>Current Opinion in Drug Discovery & Development</i> , 2002, 5(5):718-727 | |
| | C13 | Lowinger et al., "Discovery of novel class of potent Raf kinase inhibitors: structure activity relationships," <i>Clinical Cancer Research</i> , Vol. 6, Nov. 2000, 4533s | |
| | C14 | Hotte et al., "BAY 43-9006: Early Clinical Data in Patients with Advanced Solid Malignancies," <i>Current Pharmaceutical Design</i> , 2002, 8, 2249-2253 | |
| | C15 | Lee et al., "BAY-43-9006: Bayer/Onyx," <i>Current Opinion in Investigational Drugs</i> , 2003, 4(6):757-763 | |
| | C16 | Sorbara et al., "BAY-43-9006," <i>Drugs of the Future</i> , 2002, 27(12):1141-1147 - Oncolytic Raf Kinase Inhibitor. | |
| | C17 | Khire et al., "Omega-carboxypyridyl substituted ureas as raf kinase inhibitors: SAR of the amid substituent," <i>Bioorg. Med. Chem. Lett.</i> , 14 (2004), 783-786 | |
| | C18 | Wilhelm et al., "BAY 43-9006 Exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis," <i>Cancer Research</i> , 64, 7099-7109, October 1, 2004 | |
| | C19 | Smith, et al., "Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach." <i>Bioorganic & Medicinal Chemistry Letters</i> , 11 (2001) 2775-2778 | |
| | C20 | Bankston et al., "A scaleable synthesis of BAY 43-9006: a potent raf kinase inhibitor for the treatment of cancer," <i>Organic Process Research & Development</i> , 2002, 6, 777-781 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|---|--------------------------|--------------------|
| Substitute for form 1449A/PTO | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 09/889,227 |
| | | Filing Date | January 8, 2002 |
| | | First Named Inventor | Bernd RIEDL et al. |
| | | Group Art Unit | 1625 |
| | | Examiner Name | Rita J. Desai |
| | | Attorney Docket Number | BAYER-0015-A |
| Sheet | 6 | of | 10 |

| NON PATENT LITERATURE DOCUMENTS (cont'd.) | | | |
|---|-----------------------|--|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C21 | Strumberg et al., "Results of phase I pharmacokinetic and pharmacodynamic studies of the raf kinase inhibitor BAY 43-9006 in patients with solid tumors," <i>International Journal of Clinical Pharmacology and Therapeutics</i> , Vol. 40, No. 12/2002 (580-581) | |
| | C22 | Chang et al., "BAY 43-9006 (Sorafenib) inhibitors ectopic (s.c.) and orthotopic growth of a murine model of renal adenocarcinoma (Renca) predominantly through inhibition of tumor angiogenesis," 96 th Annual Meeting, April 16-20, 2005, Anaheim/Orange County, CA | |
| | C23 | Panka et al., "BAY 43-9006 induces apoptosis in melanoma cell lines," 96 th Annual Meeting, April 16-20, 2005, Anaheim/Orange County, CA | |
| | C24 | Auclair, et al., "BAY 43-9006 (Sorafenib) is a potent inhibitor of FLT3 tyrosine kinase signaling and proliferation in AML cells," 96 th Annual Meeting, April 16-20, 2005, Anaheim/Orange County, CA | |
| | C25 | Murphy et al., "BAY 43-9006 controls tumor growth through inhibition of vascular development," 96 th Annual Meeting, April 16-20, 2005, Anaheim/Orange County, CA | |
| | C26 | Spronsen et al., "Novel treatment strategies in clear-cell metastatic renal cell carcinoma," <i>Anti-Cancer Drugs</i> , 2005, 16:709-717 | |
| | C27 | Thaimattam et al., "3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies," <i>Bioorganic & Medicinal Chemistry</i> , 12(2004) 6415-6425 | |
| | C28 | Danson et al., "Improving outcomes in advanced malignant melanoma," <i>Drugs</i> , 2005, 65(6):733-743 | |
| | C29 | Heim et al., "Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006," <i>International Journal of Clinical Pharmacology and Therapeutics</i> , Vol. 41, No. 12/2003 (616-617) | |
| | C30 | Richly et al., "Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer," <i>International Journal of Clinical Pharmacology and Therapeutics</i> , Vol. 42, No. 11/204 (650-651) | |
| | C31 | Mross et al., "Drug-drug reaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors," <i>International Journal of Clinical Pharmacology and Therapeutics</i> , Vol. 41, No. 12/2003 (618-619) | |
| | C32 | Richly et al., "A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors," <i>International Journal of Clinical Pharmacology and Therapeutics</i> , Vol. 41, No. 12/2003 (620-621) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|--------------------------|--------------------|--|
| Substitute for form 1449A/PTO | | | Complete if Known | | |
| | | | Application Number | 09/889,227 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | Filing Date | January 8, 2002 | |
| | | | First Named Inventor | Bernd RIEDL et al. | |
| | | | Group Art Unit | 1625 | |
| | | | Examiner Name | Rita J. Desai | |
| | | | Attorney Docket Number | BAYER-0015-A | |
| Sheet | 7 | of | 10 | | |

(use as many sheets as necessary)

| NON PATENT LITERATURE DOCUMENTS (cont'd.) | | | |
|---|-----------------------|---|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C33 | DeGrendele, "Activity of the raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors," <i>Clinical Colorectal Cancer</i> , May 2003, pp. 16-18 | |
| | C34 | Hubbard, "Oncogenic mutations in B-Raf: some losses yield gains," Skirball Institute of Biomolecular Medicine and Department of Pharmacology, New York University School of Medicine, New York, NY | |
| | C35 | Thompson et al., "Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery," <i>Curr. Opin. Pharmacol.</i> , 2005 Aug., 5(4):350-6 | |
| | C36 | Moore et al., "Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors," <i>Annals of Oncology</i> , 16:1688-1694, 2005 | |
| | C37 | Ahmad et al., "Kinase inhibition with BAY 43-9006 in renal cell carcinoma," <i>Clinical Cancer Research</i> , Vol. 10, 6388s-6392s, 15 Sept. 2004 | |
| | C38 | Wan et al., "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF," <i>Cell</i> , Vol. 116, 855-867, 19 March 2004 | |
| | C39 | Hanson, "Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis, Inhibitors of p38 kinase," <i>Exp. Opin. Ther. Patents</i> , (1997) 7(7):729-733 | |
| | C40 | Strumberg et al., "Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors," <i>Journal of Clinical Oncology</i> , Vol. 23, No. 5, 10 Feb. 2005, 965-972 | |
| | C41 | Regan et al., "Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate," <i>J. Med. Chem.</i> , 2002, 45, 2994-3008 | |
| | C42 | Clark et al., "Safety and pharmacokinetics of the dual action raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors," <i>Clin. Cancer Res.</i> , 2005:11(15), 1 August 2005, 5472-5480 | |
| | C43 | Wilson et al., "The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase," <i>Chemistry & Biology</i> , 1997, Vol. 4, No. 6, 423-431 | |
| | C44 | Jeffcoat et al., "The metabolism and toxicity of halogenated carbanilides," <i>Drug Metabolism and Deposition</i> , Vol. 5, No. 2, 157-166 | |
| | C45 | Murata et al., "Facile synthesis of new pyrrolo[3,4-d]pyrimidine-2,4-diones," <i>Chem. Pharm. Bull.</i> , 22(5) 1212-1213 (1974) | |

| | | |
|--------------------|--|-----------------|
| Examiner Signature | | Date Considered |
|--------------------|--|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|---|--------------------------|--------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Application Number | 09/889,227 |
| | | Filing Date | January 8, 2002 |
| | | First Named Inventor | Bernd RIEDL et al. |
| | | Group Art Unit | 1625 |
| | | Examiner Name | Rita J. Desai |
| | | Attorney Docket Number | BAYER-0015-A |
| Sheet | 8 | of | 10 |

| NON PATENT LITERATURE DOCUMENTS (cont'd.) | | | |
|---|-----------------------|--|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C46 | Iwadata Y. et al, "Intra-arterial ACNU, CDDP chemotherapy for brain metastases from lung cancer: comparison of cases with and without intra-arterial mannitol infusion," <i>Neurol. Surg.</i> , (1993) vol. 21, no. 6, pp. 513-518 | |
| | C47 | Hanson, "Inhibitors of p38 kinase," <i>Expert Opinion on Therapeutic Patents</i> , July 1997, vol. 7, no. 7, pp. 729-733(5) | |
| | C48 | Garcia-Lopez et al., "New routes for the synthesis of pyrrolo[3,2-d]- and -[2,3-d]pyrimidine systems starting from a common pyrrole derivative," <i>Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999)</i> (1978), (5), 483-7 | |
| | C49 | Willhelm et al., "BAY 43-9006: preclinical data," <i>Curr Pharm Des</i> , 2002, 8(25):2255-7 | |
| | C50 | Wright et al., "Clinical trials referral resource. Current clinical trials of BAY 43-9006, Part 1," <i>Oncology</i> , 2005 Apr, 19(4):499-502 | |
| | C51 | Dumas, "Protein kinase inhibitors from the ureas class," <i>Current Opinion in Drug Discovery & Development</i> , 2002, Vol. 5, No. 5, 718-727 | |
| | C52 | Patent Abstracts of Japan, Publication No. 02-023337, published 01-28-1990 | |
| | C53 | Patent Abstracts of Japan, Publication No. 02-022650, published 01-25-1990 | |
| | C54 | Wissner et al., "Analogues of platelet activating factor. 7. Bis-aryl amide and bis-aryl urea receptor antagonists of PAF," <i>J. Med. Chem.</i> , 1992, 35, 4779-4789 | |
| | C55 | Ravi et al., "Activated raf-1 causes growth arrest in human small cell lung cancer cells," <i>J. Clin. Invest.</i> , pp. 153-159 | |
| | C56 | Lemoine, "Overview of ras oncogenes and their clinical potential," Chapter 10, | |
| | C57 | <i>Drug, facts and comparisons</i> , 1994 Edition, pp. 2703-2705 | |
| | C58 | Siu et al, "Phase I study of oral raf-1 kinase inhibitor BAY 43-9006 with gemcitabine in patients with advanced solid tumors," <i>Proc Am Soc Clin Oncol</i> , 22:207, 2003 (abstr 828) | |
| | C59 | Escudier et al., "Randomized phase III trial of the raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)," Meeting: 2005 ASCO Annual Meeting, Category: Genitourinary Cancer, Subcategory: Kidney Cancer, Abstract No. 4510 | |
| | C60 | Eisen et al., "Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients," Meeting: 2005 ASCO Annual Meeting, Category: Melanoma, Subcategory: Melanoma, Abstract No. 7508 | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | |
|--|---|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO | | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | Application Number | 09/889,227 |
| | | | Filing Date | January 8, 2002 |
| | | | First Named Inventor | Bernd RIEDL et al. |
| | | | Group Art Unit | 1625 |
| | | | Examiner Name | Rita J. Desai |
| | | | Attorney Docket Number | BAYER-0015-A |
| Sheet | 9 | of | 10 | |

(use as many sheets as necessary)

| NON PATENT LITERATURE DOCUMENTS (cont'd.) | | | |
|---|-----------------------|--|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C61 | Adjei et al., "A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC)," Meeting: 2005 ASCO Annual Meeting, Category: Developmental Therapeutics: Molecular Therapeutics, Subcategory: Antiangiogenic or Antimetastatic agents, Abstract No. 4510 | |
| | C62 | Carling et al., "1-(3-cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1,3-dihydroimidazol-2-one: A selective high-affinity antagonist for the human dopamine D ₄ receptor with excellent selectivity over ion channels," <i>J. Med. Chem.</i> , 1999, 42, 2706-2715 | |
| | C63 | Van Muijlwijk-Koezen et al., "Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A ₃ receptor," <i>J. Med. Chem.</i> , 2000, 43, 2227-2238 | |
| | C64 | Eisenhauer et al., "Impact of new non-cytotoxics in the treatment in ovarian cancer," <i>Int. J. Gynecol. Cancer</i> , 2001, 11 (Suppl. 1), 68-72 | |
| | C65 | Kubo et al., "Synthesis and structure-activity relationship of quinazoline-urea derivatives as novel orally active VEGF receptor tyrosine kinase selective inhibitors," #913, XP-001152608 | |
| | C66 | Carter et al, "Anti-tumor efficacy of the orally active raf kinase inhibitor BAY 43-9006 in human tumor xenograft models," #4954, XP-001145482 | |
| | C67 | Strumberg et al., "Phase I and pharmacokinetic study of the raf kinase inhibitor bay 43-9006 in patients with locally advanced or metastatic cancer," #2921, XP-001145481 | |
| | C68 | Dumas et al., "1-phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors," <i>Bioorganic & Medicinal Chemistry Letters</i> , 10 (2000), 2051-2054 | |
| | C69 | Riedl et al., "Potent raf kinase inhibitors from the diphenylurea class: structure activity relationships," #4956, XP-001145518 | |
| | C70 | Iwadate et al., "Intra-arterial ACNU, CDDP chemotherapy for brain metastases from lung cancer: comparison of cases with and without intra-arterial mannitol infusion," Dept of Neurological Surgery, Chiba Cancer Center Hospital, Clinical Trial, Journal Article, Randomized Controlled Trial, Vol. 21, No. 6, 513-518 | |
| | C71 | Geiger et al., "Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice," <i>Clinical Cancer Research</i> , Vol. 3, 1179-1185, July 1997 | |
| | C72 | Cunningham et al., "A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma," <i>Cancer</i> , September 2001, Vol. 92, No. 5, 1265-1271 | |
| | C73 | Madwed et al., "Pharmacological Evaluation of BIRB 796, a selective inhibitor of P38 MAP Kinase (MAPK), in animal models of endotoxic shock, inflammation and arthritis," <i>Inflammation Res.</i> , 50:S184, 2001. | |
| | C74 | Blanco, "p38 MAPK signaling cascades: ancient roles and new functions," <i>Bioassays</i> , 22:637-645, 2000 | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|--|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Application Number | 09/889,227 |
| | | Filing Date | January 8, 2002 |
| | | First Named Inventor | Bernd RIEDL et al. |
| | | Group Art Unit | 1625 |
| | | Examiner Name | Rita J. Desai |
| | | Attorney Docket Number | BAYER-0015-A |
| Sheet | 10 | of | 10 |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|--------------------------|---|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C76 | Redman, A. M.; Johnson, J. S.; Dally, R.; Swartz, S.; Wild, H.; Paulsen, H.; Caringal, Y.; Gunn, D.; Renick, J.; Osterhout, M.; Kingery-Wood, J.; Smith, R. A.; Lee, W.; Dumas, J.; Wilhelm, S. M.; Housley, T. J.; Bhargava, A.; Ranges, G. E.; Shrikhande, A.; Young, D.; Bombara, M.; Scott W. J. "P38 Kinase Inhibitors for the Treatment of Arthritis and Osteoporosis: Thienyl, Furyl and Pyrrolyl Ureas" Bioorg. Med. Chem. Lett. 2001, 11 (1), 9. | |
| | C77 | Dumas, J.; Hatoum-Mokdad, H.; Sibley, R. N.; Smith, R. A.; Scott, W. J.; Khire, U.; Lee, W.; Wood, J.; Wolanin, D.; Cooley, J.; Bankston, D.; Redman, A. M.; Schoenleber, R.; Caringal, Y.; Gunn, D.; Romero, R.; Osterhout, M.; Paulsen, H.; Housley, T. J.; Wilhelm, S. M.; Bhargava, A.; Pirro, J.; Chien, D.-S.; Ranges, G. E.; Shrikhande, A.; Muzsi, A.; Bortolon, E.; Wakefield, J.; Gianpaolo-Ostravage, C.; Chau, T. "Synthesis and Pharmacological Characterization of a Potent, Orally Active p38 Kinase Inhibitor" Bioorg. Med. Chem. Lett. 2002, 12, 1559. | |
| | C78 | Dumas, J. "Protein Kinase Inhibitors from the Urea Class" Curr. Opin. Drug Discov. Dev. 2002, 5(5), 715-724. | |
| | C79 | Dumas, J.; Sibley, R.; Riedl, B.; Monahan, M.-K.; Lee, W.; Lowinger, T. B.; Redman, A. M.; Johnson, J. S.; Kingery-Wood, J.; Scott, W. J.; Smith, R. A.; Bobko, M.; Schoenleber, R.; Ranges, G. E.; Housley, T. J.; Bhargava, A.; Wilhelm, S. M.; Shrikhande, A. "Discovery of a New Class of p38 Kinase Inhibitors" Bioorg. Med. Chem. Lett. 2000, 10 (18), 2047. | |
| | C80 | Proceedings of the American Association for Cancer Research - Volume 42 - March 2001 - #4957 A Novel Diphenylurea Raf-1 Kinase Inhibitor (RKI) Blocks the Raf/Mek/Erk Pathway in Tumor Cells. Scott McClelland Wilhelm et al., Bayer Corporation. | |

| | | |
|-----------------------|--------------------|--|
| Examiner Signature | Date Considered | |
|-----------------------|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.